Pathfinder Cell Therapy, Inc. (PFND) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pathfinder Cell Therapy, Inc. (PFND) trades at $0.0001 with AI Score 42/100 (Grade C). Pathfinder Cell Therapy, Inc. is a development stage regenerative medicine company focusing on cell-derived therapies for diseases characterized by organ-specific cell damage. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PFND: PFND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PFND against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PFND: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pathfinder Cell Therapy, Inc. (PFND) Healthcare & Pipeline Overview
Pathfinder Cell Therapy, Inc., founded in 2008, is a development-stage biotech firm focused on regenerative medicine. The company is pioneering cell-derived therapies targeting diseases with organ-specific cell damage, including diabetes and cardiovascular conditions. It operates in the competitive biotechnology sector, facing established players and regulatory hurdles.
What Is the Investment Thesis for PFND?
Pathfinder Cell Therapy, Inc. presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's focus on cell-derived therapies targeting organ-specific cell damage addresses a significant unmet medical need. Successful development and commercialization of these therapies could generate substantial returns. However, the company faces significant challenges, including the lengthy and expensive regulatory approval process, the need for substantial capital investment, and competition from established pharmaceutical companies. The company's market capitalization is currently $0.00B, reflecting its development stage and the inherent risks associated with biotechnology investments. Key value drivers include successful completion of clinical trials, regulatory approvals, and strategic partnerships. Upcoming catalysts include the progression of its therapies through clinical trial phases.
Based on FMP financials and quantitative analysis
PFND Key Highlights
Pathfinder Cell Therapy, Inc. is a development stage company, focusing on novel cell-derived therapies.
- The company targets diseases characterized by organ-specific cell damage, including diabetes and cardiovascular conditions.
- The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
- The company's P/E ratio is -0.04, reflecting its current lack of profitability.
- The company has a beta of -24.33, indicating high volatility.
Who Are PFND's Competitors?
PFND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PFND's Key Strengths?
Novel cell-derived therapy technology.
- Focus on regenerative medicine with high growth potential.
- Potential for strong intellectual property protection.
- Addresses unmet medical needs in specific disease indications.
What Are PFND's Weaknesses?
Development stage company with no current revenue.
- High dependence on research and development success.
- Limited financial resources and small team.
- Faces significant regulatory hurdles.
What Could Drive PFND Stock Higher?
Progression of cell-derived therapies through clinical trial phases.
- Potential for strategic partnerships with pharmaceutical companies.
- Regulatory approvals from FDA or EMA.
- Research and development of new therapies.
- Expansion into new therapeutic areas.
What Are the Key Risks for PFND?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trials and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Failure to secure funding for ongoing research.
- Technological obsolescence.
- Limited financial resources and small team.
What Are the Growth Opportunities for PFND?
- Expansion into New Therapeutic Areas: Pathfinder Cell Therapy has the opportunity to expand its research and development efforts into new therapeutic areas beyond its current focus on diabetes, renal disease, myocardial infarction, and peripheral vascular disease. By exploring the potential of its cell-derived therapies in other diseases characterized by organ-specific cell damage, the company can broaden its market reach and increase its revenue potential. The market for regenerative medicine therapies is expanding rapidly, with new applications emerging in areas such as neurodegenerative diseases and autoimmune disorders. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Pathfinder Cell Therapy can pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its therapies. These partnerships can provide access to funding, expertise, and resources that can help the company navigate the complex regulatory landscape and bring its products to market more quickly. The pharmaceutical industry is increasingly relying on collaborations with smaller biotechnology firms to access innovative technologies and expand their product pipelines. Timeline: Ongoing.
- Advancement of Clinical Trials: Pathfinder Cell Therapy's success hinges on its ability to advance its therapies through clinical trials and demonstrate their efficacy and safety. Positive results from clinical trials can attract investment, generate partnerships, and ultimately lead to regulatory approval and commercialization. The clinical trial process is lengthy and expensive, but it is essential for bringing new therapies to market. The company must carefully manage its clinical trial programs and ensure that they are well-designed and executed. Timeline: Ongoing.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is critical for Pathfinder Cell Therapy to commercialize its therapies. The regulatory approval process is complex and requires extensive data on the safety and efficacy of the therapies. The company must navigate the regulatory landscape effectively and ensure that its therapies meet all the necessary requirements. Timeline: Upcoming.
- Expansion into International Markets: Pathfinder Cell Therapy can expand its market reach by commercializing its therapies in international markets. The demand for regenerative medicine therapies is growing globally, driven by an aging population and increasing prevalence of chronic diseases. The company must navigate the regulatory and cultural differences in different markets to successfully commercialize its products internationally. Timeline: Ongoing.
What Are PFND's Competitive Advantages?
- Proprietary cell-derived therapy technology.
- Focus on specific disease indications with unmet medical needs.
- Potential for strong intellectual property protection through patents.
What Does PFND Do?
Pathfinder Cell Therapy, Inc., established in 2008, is a regenerative medicine company dedicated to developing innovative cell-derived therapies. The company's primary focus is on addressing diseases and medical conditions characterized by organ-specific cell damage. Pathfinder Cell Therapy identifies diabetes, renal disease, myocardial infarction, and peripheral vascular disease as potential indications for its technology. The company's research and development efforts are centered on creating therapies that can regenerate or repair damaged cells within specific organs, offering potential treatments for a range of debilitating conditions. Headquartered in Cambridge, Massachusetts, Pathfinder Cell Therapy operates as a development-stage company, meaning its primary activities revolve around research, preclinical studies, and clinical trials. As of 2026, the company has a small team of employees. Pathfinder Cell Therapy's success hinges on its ability to navigate the complex regulatory landscape, secure funding for ongoing research, and demonstrate the efficacy and safety of its cell-derived therapies in clinical trials.
What Products and Services Does PFND Offer?
- Develops cell-derived therapies for regenerative medicine.
- Targets diseases characterized by organ-specific cell damage.
- Focuses on indications like diabetes, renal disease, myocardial infarction, and peripheral vascular disease.
- Conducts research and preclinical studies to evaluate therapy efficacy.
- Seeks to regenerate or repair damaged cells within specific organs.
- Aims to provide potential treatments for debilitating conditions.
How Does PFND Make Money?
- Focuses on research and development of cell-derived therapies.
- Seeks to generate revenue through licensing agreements and partnerships.
- Aims to commercialize therapies upon successful clinical trials and regulatory approvals.
What Industry Does PFND Operate In?
Pathfinder Cell Therapy operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for growth. The regenerative medicine market, a subset of the biotechnology industry, is projected to experience substantial growth in the coming years, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes established pharmaceutical companies, as well as smaller biotechnology firms focused on regenerative medicine. Pathfinder Cell Therapy's success depends on its ability to differentiate its therapies, secure funding, and navigate the regulatory landscape.
Who Are PFND's Key Customers?
- Pharmaceutical companies seeking innovative therapies.
- Healthcare providers treating diseases with organ-specific cell damage.
- Patients suffering from diabetes, renal disease, myocardial infarction, and peripheral vascular disease.
Company Profile
Pathfinder Cell Therapy, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Richard L. Franklin. PFND has traded publicly since 2000.
Financial Health
Pathfinder Cell Therapy, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Pathfinder Cell Therapy, Inc. stands at 31.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
PFND Valuation & Market Position
Relative to its peer group, PFND's quantitative score of 42/100 is below the peer average of 76/100.
PFND Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their cell therapy technology.
- Increased media coverage over the past month has raised awareness about the company's innovative approaches, attracting new interest.
- Strategic partnerships announced recently may enhance their research capabilities and market reach, fostering optimism among investors.
Bear Case
- Concerns about the regulatory environment for cell therapies remain, with potential delays impacting product development timelines.
- Social media discussions have revealed skepticism regarding the scalability of their technology, raising doubts among some investors.
- Recent market volatility has led to a more cautious stance from some community members, who are wary of investing in high-risk sectors.
- Comparisons to other biotech firms facing similar challenges suggest that Pathfinder may struggle to differentiate itself in a competitive landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PFND Latest News
No recent news available for PFND.
PFND Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PFND.
Price Targets
Wall Street price target analysis for PFND.
PFND MoonshotScore
What does this score mean?
The MoonshotScore rates PFND 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard L. Franklin
Managing
Richard L. Franklin is the managing employee of Pathfinder Cell Therapy, Inc. Information regarding his detailed career history, education, and previous roles is not available. His leadership is crucial for guiding the company through its development stage and navigating the complexities of the biotechnology industry. His experience in regenerative medicine and cell-derived therapies, if any, would be a significant asset to the company.
Track Record: Due to the limited information available, it is difficult to assess Richard L. Franklin's track record at Pathfinder Cell Therapy, Inc. Key milestones and strategic decisions under his leadership are not publicly known. The company's progress in advancing its therapies through clinical trials and securing regulatory approvals will be a key indicator of his success.
PFND OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. These companies are not required to adhere to the same stringent reporting standards, making it difficult for investors to assess their financial health and operational performance. The OTC Other tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited or no financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Investigate the background of the company's management team.
- Attempt to obtain financial statements, even if not publicly available.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with the company's industry and operations.
- Consult with a financial advisor before investing.
- Be wary of unsolicited investment offers or guarantees of high returns.
- Company has been in operation since 2008.
- Focus on regenerative medicine, a growing field.
- Headquartered in Cambridge, Massachusetts, a biotech hub.
Common Questions About PFND (Healthcare)
What does the AI Score mean for PFND?
PFND holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Pathfinder Cell Therapy, Inc. is a development stage regenerative medicine company focusing on cell-derived therapies for diseases characterized by organ-specific cell damage. The company targets …
What does Pathfinder Cell Therapy, Inc. do?
Pathfinder Cell Therapy, Inc. is a development-stage regenerative medicine company focused on creating cell-derived therapies for diseases characterized by organ-specific cell damage. The company aims to address conditions like diabetes, renal disease, myocardial infarction, and peripheral vascular disease by developing therapies that regenerate or repair damaged cells within specific organs.
What do analysts say about PFND stock?
As of 2026-03-16, there is no available analyst coverage for Pathfinder Cell Therapy, Inc. due to its OTC listing and development stage. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own thorough research and consider the inherent risks associated with investing in a development-stage biotechnology company on the OTC market. Growth considerations include successful clinical trials, regulatory approvals, and strategic partnerships.
What are the main risks for PFND?
Pathfinder Cell Therapy, Inc. faces several significant risks inherent to its development stage and industry. These include the risk of unsuccessful clinical trials, which could halt the development of its therapies. Regulatory setbacks, such as failure to obtain FDA or EMA approval, could also prevent commercialization. Competition from established pharmaceutical companies with greater resources poses a threat.
What are the key factors to evaluate for PFND?
Pathfinder Cell Therapy, Inc. (PFND) holds an AI score of 42/100 (low). presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. Not financial advice.
How frequently does PFND data refresh on this page?
PFND's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PFND's recent stock price performance?
Pathfinder Cell Therapy, Inc. (PFND) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel cell-derived therapy technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PFND overvalued or undervalued right now?
Pathfinder Cell Therapy, Inc. (PFND) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PFND before investing?
Before investing in Pathfinder Cell Therapy, Inc. (PFND), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and development stage.
- Financial data is limited and may not be up-to-date.
- Analyst coverage is non-existent.